Table 1.

Patient characteristics: sex (F, female, M, male), age (in years), KPS, prior treatments before enrollment in this trial (RT, radiotherapy; TMZ, temozolomide), received viral dose (vp), if patients underwent resection prior to treatment, and isocitrate dehydrogenase (IDH) status.

				Prior treatment
Patient	Sex	Age	KPS	Standard therapy	Second-line	Third-line	Dose (vp)	Resection	IDH status
1	F	42	90	Resection, RT/TMZ, aTMZ	Bevacizumab + lomustine		107	Yes	Wild-type
2	F	29	90	Resection, RT/TMZ, aTMZ	Bevacizumab + lomustine		107	No	n/a
3	M	54	80	Resection, RT	Temsirolimus	Bevacizumab + lomustine	107	No	Wild-type
4	F	46	90	Resection, RT/TMZ, aTMZ	Lomustine		108	No	Wild-type
5	M	53	100	Resection, RT/TMZ, aTMZ	Bevacizumab + lomustine		108	No	Wild-type
6	F	60	90	Resection, RT, TMZ			108	Yes	Wild-type
7	M	67	80	Resection, RT/TMZ	Dasatinib + lomustine		109	No	Wild-type
8	M	64	90	Resection, RT/TMZ, aTMZ	Lomustine		109	No	n/a
9	M	60	90	Resection, RT/TMZ	DC therapy	Lomustine	109	No	n/a
10	F	54	90	Biopsy, RT, TMZ	Lomustine		1010	No	Wild-type
11	F	48	80	Resection, RT/TMZ	Re-resection, aTMZ		1010	No	Wild-type
12	M	52	90	Resection, RT/TMZ, aTMZ			1010	Yes	Wild-type
13	M	45	90	Resection, RT/TMZ, aTMZ	Re-resection, lomustine		3 × 1010	No	Wild-type
14	M	37	90	Resection, re-resection, TMZ, RT	Lomustine		Not infused	No	n/a
15	F	40	100	Resection, RT/TMZ, aTMZ	Lomustine		3 × 1010	No	Mutant
16	M	55	100	Resection, RT/TMZ, aTMZ			1010	No	Wild-type
17	F	66	90	Resection, RT/TMZ, aTMZ	Bevacizumab + lomustine	Re-resection	1010	Yes	Wild-type
18	M	69	90	Resection, RT/TMZ,	Re-resection, aTMZ	Re-resection	1010	Yes	Wild-type
19	M	38	80	Resection, RT/TMZ, aTMZ	Bevacizumab + lomustine		1010	No	Wild-type
20	M	56	80	Resection, RT/TMZ, aTMZ	Re-resection, lomustine		1010	No	Wild-type